The company based in Okinawa, the most southern part of Japan, is developing a naturally-derived anti-fungal drug compound with a very unique chemical structure. The company reports that the structure is brand new and is actually filing 3 patents in Japan as well as international application in the EU with the European Patent Convention, United States, Canada, China and South Korea.
The compound was isolated from fermentation products of a new species of Streptomyces that were collected in soil of Japanese South-West Islands also nicknamed as “last frontier”.
This compound is developed for trichophytosis unguium, the so called “nail athlete’s foot disease” caused by fungal infections.
The company has been performing pre-clinical studies where both acute toxicity and efficacy tests were cleared confirming therefore the compound therapeutic effects that are at least twice more efficient than the drugs actually on the market.
The company is now going to execute chronic toxicity test under GLP (Good Laboratory Practice) management followed by clinical study.
For further phase of research and development the company is looking for a partner who would provide financial support and/or who would license their compound.
In case of a licensing agreement, the company will be supporting the EU partner until completion of technical transfer of the compound. During that stage, the partner will also be able to receive advice from researches of this new drug, who are taking advantage of the Japanese company’s special technology for sample screenings.